Skip to content

Vitamin C with levothyroxine in primary hypothyroidism

Effect of vitamin C and levothyroxine on thyroid function in patients with primary hypothyroidism

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180220038807N1
Enrollment
189
Registered
2018-05-30
Start date
2018-05-05
Completion date
Unknown
Last updated
2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypothyroidism.

Interventions

Intervention 1: Intervention group: Patients will receive levothyroxine 0.1 mg and vitamin C 1000 mg daily. Intervention 2: Intervention group: Patients will receive levothyroxine 0.1 mg and vitamin C

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The age of 18 to 75 years of both sexes is male and female The level of patient's TSH when entering the study is between 0.5 and 4.5 Miu / l At least six months, the patient's dose of levothyroxine has not changed

Exclusion criteria

Exclusion criteria: Patients with thyroid cancer, chronic gastrointestinal diseases, celiac disease, lactose intolerance, intestinal infections (Giardia lamblia), chronic lung, kidney and liver disease (cirrhosis), kidney stones, or history of kidney stones, CHF, vitamin B12 deficiency, pancreatic insufficiency As well as patients with jejunostyle or jejunoileal bypass, suffering from short-systolic syndrome or autoimmune gasteritis and H.Pylori infection Pregnant, lactating and purpose to pregnancy women Hormone-treated patients, such as taking contraceptives or estrogen and testosterone over the past three months Patients treated with any of the following drugs or compounds: ferrous sulfate, calcium carbonate, colestipol, aluminum hydroxide, sucralfate, propranolol, laxatives, levostatin, solvate ester (sevelamer), cromium picolinate, bile acid sequestrants Gastric acid antacids, sucralfate, sodium polysterone sulfonate, cholesterol, dopamine analogues, steroids, somatostatin and also anticonvulsants, raloxifene, cimetidine, amiodarone, sertraline and activated charcoal. Patients who have a change in their TSH for more than 1 unit in the first 8 weeks of their study or who have complications of vitamin C (severe nausea and vomiting or severe diarrhea)

Design outcomes

Primary

MeasureTime frame
Thyroid function test levels. Timepoint: Before and 8 weeks after intervention. Method of measurement: By measuring serum levels of TSH and T4.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Alipour

Arak University of Medical Sciences

m.alipour@arakmu.ac.ir+98 86 3417 3601

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026